NCT03688451 is a Phase 2 clinical trial of Rituximab in Non Hodgkin Lymphoma, sponsored by Tahir Latif.

Who is sponsoring NCT03688451?

NCT03688451 is sponsored by Tahir Latif.

What drugs are being tested in NCT03688451?

Interventions in NCT03688451: Rituximab.

What condition does NCT03688451 study?

NCT03688451 studies Non Hodgkin Lymphoma.

Is NCT03688451 still recruiting?

NCT03688451 is currently status unknown. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT03688451

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

Status unknown Phase 2 Last updated 29 March 2023

What this trial tests

Phase 2 trial testing Rituximab in Non Hodgkin Lymphoma in 20 participants. Status unknown.

Timeline

29 October 2018

Primary endpoint
1 December 2023

1 October 2024

Quick facts

Lead sponsor	Tahir Latif
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	29 October 2018
Primary completion	1 December 2023
Estimated completion	1 October 2024
Sites	1 location across United States

Drugs / interventions tested

Rituximab — full drug profile →

Conditions studied

Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →

Sponsor

Tahir Latif

Who can join

18 and older, any sex, with Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma.
Chua BJG, Low CE, Yau CE, Tan YH, et al · · 2024 · cited 7× · PMID 38173015 · DOI 10.1186/s40164-023-00467-2

Verify or expand the search:

Other trials of Rituximab

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting

Other recruiting trials for Non Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03688451 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tahir Latif
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03688451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing